Frontiers of CGT in China

China is at the forefront of global cell and gene therapy (CGT) development

According to Nature research in 2021, China accounts for over 50 percent of cell therapy trials worldwide. Today, there are around 400 ongoing CAR-T trials in China across a broad range of targets and diverse indications, from hematology/oncology to solid tumors.

Among the frontrunners, Fosun Kite’s Yescarta and JW Therapeutics’ Relma-cel received approval from the National Medical Products Administration (NMPA) in 2021, marking a new era for cell therapy in China. More recently, new drug approvals (NDAs) of B-cell-maturation-antigen-targeted (BCMA-targeted) CAR-T therapies from CARsgen and IASO Biotherapeutics/Innovent were accepted by the NMPA in October 2022. Formal approval and commercialization of these therapies are expected in the coming months.

Compared to…